On November 24, Oskar Mellgren, Chairman of the Board of Scandinavian Real Heart, acquired 7,200 shares in the company.
The shares were purchased at a price of SEK 14 each, corresponding to a total transaction amount of SEK 100,800. The transaction was carried out on Nasdaq First North Growth Market and is listed in the Swedish Financial Supervisory Authority's transparency register.
After the purchase, Oskar now holds a total of 7,200 shares in the company.
Den 24 november förvärvade Oskar Mellgren, styrelseordförande i Scandinavian Real Heart, 7 200 aktier i bolaget.
Aktierna köptes till en kurs om 14 kronor styck, motsvarande en total transaktionssumma på 100 800 kronor. Transaktionen genomfördes på Nasdaq First North Growth Market och framgår av Finansinspektionens insynsregister.
Efter köpet innehar Oskar nu totalt 7 200 aktier i bolaget.
Styrelsen i Scandinavian Real Heart AB (publ) kallade den 24 oktober 2025 till en extra bolagsstämma planerad att hållas den 24 november 2025. Kallelsen har dock inte publicerats i Post- och Inrikes Tidningar, vilket är ett lagstadgat krav enligt Aktiebolagslagen.
Med anledning av detta har styrelsen beslutat att ändra datum för den extra bolagsstämman. Ny kallelse har skickats ut den 13 november 2025 i enlighet med gällande regelverk. Det nya datumet för den extra bolagsstämman är den 16 december 2025, kl. 17.30 på Best Western Plus Hotel Plaza, Kopparbergsvägen 10, 722 13 Västerås. Inregistrering till stämman börjar kl. 17.00.
Vi beklagar det inträffade och arbetar för att säkerställa att processen följer alla lagstadgade krav.
Fullständig kallelse inklusive bilagor finns tillgänglig på vår hemsida:
https://www.realheart.se
De ärenden som ska behandlas vid stämman kvarstår oförändrade.
On October 24, 2025, the Board of Directors of Scandinavian Real Heart AB (publ) convened an Extraordinary General Meeting scheduled to be held on November 24, 2025. However, the notice has not been published in the Swedish Official Gazette, which is a statutory requirement under the Swedish Companies Act.
Due to this, the Board of Directors has decided to change the date of the Extraordinary General Meeting. A new notice has been sent out on 13 November 2025 in accordance with current regulations. The new date for the Extraordinary General Meeting is 16 December 2025 at 5:30 p.m. at Best Western Plus Hotel Plaza, Kopparbergsvägen 10, 722 13 Västerås, Sweden. Registration for the meeting will commence at 5:00 p.m.
We apologize for the inconvenience and are working to ensure that the process complies with all legal requirements.
The complete notice including appendices is available on our website:
https://www.realheart.se
Matters to be dealt with at the Annual General Meeting remain unchanged.
Aktieägarna i Scandinavian Real Heart AB, org.nr. 556729-5588 (”Bolaget”), kallas härmed till extra bolagsstämma den 16 december 2025 kl. 17.30 på Best Western Plus Hotel Plaza, Kopparbergsvägen 10, 722 13 Västerås. Inregistrering till stämman börjar kl. 17.00.
Rätt att delta vid stämman m.m.
Aktieägare som önskar delta vid stämman ska:
För att ha rätt att delta i stämman måste en aktieägare som låtit förvaltarregistrera sina aktier, förutom att anmäla sig till stämman, låta registrera aktierna i eget namn så att aktieägaren blir upptagen i framställningen av aktieboken per avstämningsdagen den 8 december 2025. Sådan omregistrering kan vara tillfällig (s.k. rösträttsregistrering) och begärs hos förvaltaren enligt förvaltarens rutiner i sådan tid i förväg som förvaltaren bestämmer. Rösträttsregistrering som gjorts av förvaltaren senast den 8 december 2025 kommer att beaktas vid framställningen av bolagsstämmoaktieboken.
Ombud m.m.
Om aktieägare ska företrädas av ombud måste ombudet ha med skriftlig, daterad och av aktieägaren undertecknad fullmakt till stämman. Fullmakten får inte vara äldre än ett år om den inte anger att den är giltig under en längre tid, dock längst fem år. Om fullmakten utfärdats av juridisk person ska ombudet också ha med aktuellt registreringsbevis eller motsvarande behörighetshandling för den juridiska personen. För att underlätta inpasseringen bör kopia av fullmakt och andra behörighetshandlingar bifogas anmälan till stämman. Fullmaktsformulär hålls tillgängligt på Bolagets hemsida www.realheart.se och skickas med post till aktieägare som kontaktar Bolaget och uppger sin adress.
Behandling av personuppgifter
För information om hur personuppgifter behandlas i samband med bolagsstämman hänvisas till den integritetspolicy som finns tillgänglig på Euroclear Sweden AB:s hemsida: https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.
Förslag till dagordning
Punkt 1 – Val av ordförande vid stämman
Styrelsen föreslår att Jimmy Nybom väljs till ordförande på stämman.
Punkt 7 – Beslut om nyemission av aktier
Styrelsens förslag till beslut om nyemission av aktier, bilaga 1
Punkt 8 – Beslut om ändring av bolagsordningen
Styrelsens förslag till beslut om ändring av bolagsordningen, bilaga 2
Den föreslagna bolagsordningen i sin helhet, bilaga 3
Beslutet är villkorat av att stämman fattar beslut i enlighet med punkten 7 i kallelsen.
Majoritetskrav
För giltigt beslut enligt beslutspunkten 8 krävs att förslagen biträds av aktieägare med minst två tredjedelar av såväl de avgivna rösterna som de aktier som är företrädda vid stämman.
Uppgifter om antalet aktier och röster
Vid tidpunkten för utfärdandet av denna kallelse uppgår det totala antalet aktier och röster i Bolaget till 4 998 704 stycken.
Aktieägares rätt att erhålla upplysningar
Aktieägarna erinras om rätten att vid stämman begära upplysningar från styrelsen och verkställande direktören i enlighet med 7 kap. 32 § aktiebolagslagen (2005:551).
Tillhandahållande av handlingar
Handlingar enligt aktiebolagslagen kommer att hållas tillgängliga på Bolagets kontor senast två veckor före stämman och tillsändes utan kostnad den aktieägare som begär det och uppger sin postadress. Handlingarna kommer senast från denna tidpunkt även att finnas tillgängliga på Bolagets hemsida www.realheart.se. Samtliga ovanstående handlingar kommer även att framläggas på stämman.
Västerås i november 2025
Scandinavian Real Heart AB
STYRELSEN
The shareholders of Scandinavian Real Heart AB, org.nr. 556729-5588 (the "Company"), are hereby invited to attend the Extraordinary General Meeting to be held on December 16, 2025 at 5:30 p.m. at Best Western Plus Hotel Plaza, Kopparbergsvägen 10, 722 13 Västerås, Sweden. Registration for the meeting will commence at 5:00 p.m.
Right to participate in the meeting, etc.
Shareholders who wish to participate in the Meeting must:
In order to be entitled to participate in the meeting, a shareholder whose shares are registered in the name of a nominee must, in addition to giving notice of participation in the meeting, register the shares in their own name so that the shareholder is included in the presentation of the share register as of the record date of December 8, 2025. Such re-registration may be temporary (so-called voting rights registration) and is requested from the nominee in accordance with the nominee's procedures at such time in advance as determined by the nominee. Voting rights registration made by the nominee no later than December 8, 2025 will be taken into account in the preparation of the general meeting share register.
Agents, etc.
If a shareholder is to be represented by a proxy, the proxy must bring a written, dated and signed power of attorney to the meeting. The power of attorney may not be older than one year unless it specifies that it is valid for a longer period of time, but not more than five years. If the power of attorney has been issued by a legal entity, the representative must also bring the current certificate of registration or equivalent authorization document for the legal entity. To facilitate entry, a copy of the power of attorney and other authorization documents should be attached to the notification to the meeting. Proxy forms are available on the Company's website www.realheart.se and will be sent by mail to shareholders who contact the Company and state their address.
Processing of personal data
For information on how personal data is processed in connection with the Annual General Meeting, please refer to the privacy policy available on Euroclear Sweden AB's website: https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.
Draft agenda
Item 1 – Election of Chairman of the Meeting
The Board of Directors proposes that Jimmy Nybom be elected Chairman of the Meeting.
Item 7 – Resolution on new issue of shares
The Board of Directors' proposal for a resolution on a new issue of shares, appendix 1
Item 8 – Resolution to amend the Articles of Association
The Board of Directors' proposal for a resolution to amend the Articles of Association, appendix 2
The proposed Articles of Association in its entirety, appendix 3
The resolution is conditional upon the Annual General Meeting resolving in accordance with item 7 of the notice.
Majority requirements
A valid resolution under resolution item 8 requires that the proposals are supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the meeting.
Information on the number of shares and votes
At the time of issuing this notice, the total number of shares and votes in the Company amounts to 4,998,704.
Shareholders' right to receive information
Shareholders are reminded of the right to request information from the Board of Directors and the CEO at the Annual General Meeting in accordance with Chapter 7. Section 32 of the Swedish Companies Act (2005:551).
Provision of documents
Documents in accordance with the Swedish Companies Act will be available at the Company's office no later than two weeks prior to the Annual General Meeting and will be sent free of charge to the shareholder who so requests and states their postal address. The documents will also be available on the Company's website www.realheart.se at the latest from this date. All of the above documents will also be presented at the Annual General Meeting.
Västerås in November 2025
Scandinavian Real Heart
The Board of Directors
Scandinavian Real Heart AB hereby publishes the Board’s complete proposal for a share issue, which was previously attached to the notice of the Extraordinary General Meeting on 24 October 2025
The Board of Directors propose that the General Meeting resolves on issuance of new shares, with preferential rights for the shareholders in accordance with below.
Reasons for the Offering and Use of Proceeds
Scandinavian Real Heart AB is conducting the Rights Issue of approximately SEK 70 million to secure continued financing of the Company’s development work on Realheart® TAH – a total artificial heart designed to mimic the structure and function of the human heart. The product is intended to become a permanent solution for patients suffering from severe heart failure. Previous study results support that Realheart TAH has strong potential to replace the human heart in the future.
Of the approximately 22 million patients suffering from heart failure in the EU and the US, the Company estimates that a patient population of around 160,000 with advanced (NYHA Class IV) biventricular heart failure represents the target group for TAH treatment. Furthermore, this translates into an annual number of patients requiring TAH treatment of approximately 25,000, expected to increase in line with overall heart failure prevalence to around 35,000 by 2030. The average market price for a TAH is USD 220,000, corresponding to a market potential of USD 34 billion. The US and EU are the largest markets, with Germany being the largest European market and therefore of significant interest to the Company. A collaboration with a German hospital has been initiated in preparation for future clinical trials.
In 2025, the Company deepened its collaboration with Sahlgrenska University Hospital in Gothenburg, where surgical methodology and processes have been further developed based on experience from previous animal studies. The studies are led by cardiac surgeon Professor Göran Dellgren together with a clinical team with extensive experience in heart transplantation. The objective is first to optimize surgical methodology, then conduct survival studies to compile regulatory documentation, and finally apply to initiate clinical trials.
During 2025, the Company also increased its focus on product development. The Company has produced several TAH units with improved quality and simplified manufacturing processes compared to previous versions. The Company will continue to develop production processes and product quality, both through internal initiatives and in close collaboration with carefully selected partners. As part of this work, a move to more suitable facilities will take place in 2026. The TAH units manufactured by the Company will continuously be used in endurance tests running for up to six months, as well as in animal studies and blood tests. Endurance tests of the membrane, the most critical component, have exceeded 18 months in ongoing tests. To enable the transition to clinical studies, further design improvements of the product are required, which must be validated through endurance tests, animal studies, and blood tests. This work has already begun and will continue during 2026. The company is not communicating any guidance or forecast regarding the anticipated date for the first-in-human implant. Several studies have been conducted with previous versions compared to the market-leading competitor, showing superior results in blood tests and patient simulator studies (cardiovascular simulator, so-called hybrid simulator).
If fully subscribed, the net proceeds (after estimated transaction costs of approximately SEK 300,000) are intended to be allocated as follows:
TAH Unit – 60%
Preclinical Studies – 28%
Regulatory Work – 2%
Corporate Costs – 10%
The proceeds are expected to be sufficient to finance working capital requirements for approximately 12 months.
Subscription and Guarantee Commitments
The Company has received subscription undertakings from existing shareholders, the Board of Directors, and senior management amounting to approximately SEK 25.6 million, corresponding to about 36.5% of the rights issue. In addition, the Company has obtained guarantee commitments from existing shareholders totalling approximately SEK 23.4 million, which represents about 33.5% of the rights issue. In aggregate, the rights issue is thus covered to approximately 70% by subscription and guarantee commitments. The guarantee commitments only cover the portion of the issue not subscribed for through subscription undertakings and subscriptions based on subscription rights, up to a total coverage level of 70% of the issue amount. If the rights issue is subscribed to 70% or more without the need to utilize the guarantees, the guarantee commitments will lapse. No compensation will be paid for the subscription and guarantee commitments.
Number of shares and share capital increase
The issue comprises no more than 4 998 704 new shares
The Company’s share capital may be increased by no more than SEK 25 043 507.040. The share capital increases have been calculated based on a quotient value of SEK 5.01 per share.
Right to subscribe for shares
The shareholders of the Company shall have preferential rights to subscribe for shares. For each share held on the record date, the shareholder receives one subscription right, whereby one subscription right entitles to subscribe for one share. The record date for determining which shareholders shall be entitled to subscribe for shares on a preferential basis shall be 1 December 2025.
In case not all shares have been subscribed for, the Board of Directors shall decide that allotment of shares subscribed for without subscription rights shall take place up to the maximum amount of the issue, whereby the Board of Directors primarily will allot shares to those who also subscribed for shares based on subscription rights, and in the event of over subscription, pro rata to their subscription based on subscription rights. Secondly, the Board of Directors will allot shares to those who subscribed for shares without subscription rights, and if full allotment cannot be made, the board shall have the right to freely decide on allotment.
Subscription price of shares
The subscription price is SEK 14 per share.
The share premium shall be transferred to the unrestricted premium reserve.
Subscription and payments of shares
Subscription for shares based on subscription rights shall be made through payment in cash during the period from 3 December 2025 until, and including 17 December 2025. The Board of Directors shall be entitled to extend the subscription period.
Subscription without subscription rights shall be made through notice on special application form during the period from 3 December 2025 until and including 17 December 2025. The Board of Directors shall be entitled to extend the subscription period. Payment for shares shall be made at the latest three business days following the date of the dispatch of a contract note to the subscriber, specifying allocation of shares, or such later date as the Board of Directors may decide.
Trading with subscription rights is expected to take place during the period from 3 December 2025 until, and including 12 December 2025.
Right to dividends of new shares
The new shares shall entitle to dividends as from the first record date for dividends following registration of the new shares with the Swedish Companies Registration Office.
Miscellaneous
It was furthermore proposed that the Board of Directors, the CEO, or the person ap-pointed by the Board of Directors or the CEO, shall be authorized to make such minor amendments to the resolution as may be required in connection with the registration or execution of the resolution with the Swedish Companies Registration Office or Euroclear Sweden AB.
_____________
The Board of Directors in Scandinavian Real Heart AB
Scandinavian Real Heart AB offentliggör härmed styrelsens fullständiga förslag till nyemission av aktier, vilket tidigare bifogades kallelsen till extra bolagsstämma den 24 oktober 2025
Styrelsen föreslår att bolagsstämman fattar beslut om nyemission av nya aktier med företrädesrätt för aktieägarna i enlighet med nedan.
Skäl till emissionen och användning av likviden
Scandinavian Real Heart AB genomför Företrädesemissionen om cirka 70 MSEK i syfte att säkerställa fortsatt finansiering av bolagets utvecklingsarbete med Realheart® TAH – ett totalt artificiellt hjärta utformat för att efterlikna det mänskliga hjärtats struktur och funktion. Produkten är avsedd att bli en permanent lösning för patienter med svår hjärtsvikt. Tidigare studieresultat stöder att Realheart TAH har god potential att ersätta det mänskliga hjärtat i framtiden.
Av de ca 22 miljoner patienter som lider av hjärtsvikt i EU och USA uppskattar bolaget att ett patientunderlag på ca 160 tusen patienter som lider av avancerad (NYHA class IV), biventrikulär hjärtsvikt omfattar målgruppen för TAH-behandling. Vidare uppskattas detta översättas i ett årligt antal patienter i behov av TAH-behandling till ca 25 tusen, och beräknas följa samma ökning som hjärtsvikt i stort till ca 35 tusen år 2030. Medelpriset på marknaden för ett TAH är $220 KUSD, vilket innebär en marknadspotential på $34 miljarder USD. USA och EU är de största marknaderna, varav Tyskland är den största europeiska marknaden och därav av stort intresse för bolaget. Ett samarbete med ett tyskt sjukhus har inletts inför framtida kliniska prövningar.
Under 2025 har bolaget fördjupat samarbetet med Sahlgrenska Universitetssjukhuset i Göteborg, där operationsmetodik och processer vidareutvecklats baserat på erfarenheter från tidigare djurstudier. Studierna leds av hjärtkirurg Professor Göran Dellgren tillsammans med ett kliniskt team med omfattande erfarenhet av hjärttransplantationer. Syftet är att först optimera operationsmetodiken, därefter genomföra överlevnadsstudier för att samla regulatoriskt underlag, och slutligen ansöka om att inleda kliniska prövningar.
Under 2025 har bolaget också ökat sitt fokus på produktutveckling. Bolaget har producerat ett antal enheter av TAH med förbättrad kvalitet och förenklade tillverkningsprocesser jämfört med tidigare. Bolaget kommer fortsätta utveckla produktionsprocesser och produktkvaliteten, både genom interna initiativ och i nära samarbete med noggrant utvalda samarbetspartners. Som ett led i detta arbete kommer det ske en flytt till mer ändamålsenliga lokaler under 2026. De enheter av TAH som bolaget tillverkar kommer löpande att användas i både uthållighetstester som körs kontinuerligt i upp till sex månader och djurstudier samt blodtester. Uthållighetstester av membranet, den mest kritiska komponenten har nått mer än 18 månader i pågående tester. För att möjliggöra övergången till kliniska studier krävs ytterligare designförbättringar av produkten, vilka måste valideras genom uthållighetstester, djurstudier och blodtester. Detta arbete är redan påbörjat och kommer fortgå under 2026. Bolaget lämnar inte någon prognos eller vägledning avseende det förväntade datumet för den första implantationen i människa. Flertalet studier har genomförts med tidigare versioner jämfört med marknadsledande konkurrent som visar överlägsna resultat i blodtester samt i patientsimulatorstudier (hjärtkärlsimulator, så kallad hybridsimulator).
Vid full teckning planeras likviden (efter emissionskostnader om ca 300 000 SEK) att användas enligt följande:
TAH-enheten – 60%
Prekliniska studier – 28%
Regulatoriskt arbete – 2%
Bolagskostnader – 10%
Likviditeten beräknas vara tillräcklig för att finansiera rörelsekapitalbehovet under 12 månader.
Tecknings- och garantiåtagande
Bolaget har erhållit teckningsåtaganden från befintliga aktieägare, styrelse och ledande befattningshavare om cirka 25,6 MSEK. Vilket totalt motsvarar cirka 36,5% av företrädesemissionen. Vidare har Bolaget erhållit garantiåtaganden från befintliga aktieägare om cirka 23,4 MSEK. Vilket totalt motsvarar ca 33,5% av företrädesemissionen. Sammantaget omfattas företrädesemissionen därmed till cirka 70% av tecknings- och garantiåtaganden. Garantiåtagandena omfattar endast den del av emissionen som inte täcks av teckningsåtaganden och teckning med stöd av teckningsrätter, upp till en total täckningsgrad om 70% av emissionsbeloppet. Om emissionen tecknas till 70% eller mer utan att garantin behöver utnyttjas, faller garantiåtagandena bort. Ingen ersättning utgår för tecknings- och garantiåtaganden.
Antal aktier och aktiekapitalökning
Emissionen omfattar högst 4 998 704 nya aktier
Bolagets aktiekapital kommer att kunna öka med högst 25 043 507,040 kronor. Aktiekapitalökningen är beräknad på ett kvotvärde om 5,01 kronor per aktie.
Rätt att teckna aktier
Aktier ska tecknas med företrädesrätt av Bolagets aktieägare. För varje aktie som innehas på avstämningsdagen erhåller aktieägaren en teckningsrätt, varvid en teckningsrätt berättigar till teckning av en aktie. Avstämningsdag för bestämmande av vilka aktieägare som ska vara berättigade att med företrädesrätt teckna aktier ska vara den 1 december 2025.
För det fall inte samtliga aktier tecknats med stöd av teckningsrätter ska styrelsen bestämma att tilldelning av aktier tecknade utan stöd av teckningsrätter ska äga rum inom ramen för emissionens högsta belopp, varvid styrelsen ska tilldela aktier i första hand till de som också tecknat aktier med stöd av teckningsrätter, och, vid överteckning, pro rata i förhållande till deras teckning med stöd av teckningsrätter. I andra hand ska styrelsen tilldela aktier till de som tecknat aktier utan stöd av teckningsrätter och, om full tilldelning inte kan ske äger styrelsen rätt att fritt besluta om tilldelning.
Teckningskurs för aktier
Teckningskursen är 14 kronor per aktie.
Överkurs ska tillföras den fria överkursfonden.
Teckning och betalning avseende aktier
Teckning av aktier med stöd av teckningsrätter ska ske genom kontant betalning under tiden från och med den 3 december 2025 till och med den 17 december 2025. Styrelsen ska äga rätt att förlänga teckningstiden.
Teckning av aktier utan stöd av teckningsrätter ska ske genom anmälan på särskild anmälningssedel under tiden från och med den 3 december 2025 till och med den 17 december 2025. Styrelsen ska äga rätt att förlänga teckningstiden. Betalning för tecknade aktier ska erläggas senast tredje bankdagen efter att avräkningsnota som utvisar besked om tilldelning avsänts till tecknaren, eller sådant senare datum som styrelsen bestämmer.
Handel med teckningsrätter beräknas ske under tiden från och med den 3 december 2025 till och med den 12 december 2025.
Rätt till utdelning för nya aktier
De nya aktierna ska medföra rätt till vinstutdelning första gången på den avstämningsdag för utdelning som infaller efter det att aktierna har registrerats hos Bolagsverket.
Övrigt
Vidare föreslås att styrelsen, den verkställande direktören, eller den som styrelsen eller den verkställande direktören utser, ska bemyndigas att vidta de smärre ändringar i beslutet som kan visa sig erforderliga i samband med registrering eller verkställighet av beslutet hos Bolagsverket eller Euroclear Sweden AB.
_____________
Styrelsen i Scandinavian Real Heart AB
Västerås, Sweden, November 5, 2025 – Scandinavian Real Heart AB (publ) announces today that the company has been granted patent approvals in China and Japan. The patents concern both the core technology of Realheart® TAH, pertaining to the structure and function of the total artificial heart, and the integrated feedback mechanism that regulates the device’s cardiac output. The recent approvals grant protection in China until 2041, and in Japan until 2041.
Patent 1: patent in China covering a pressure sensor for Realheart® TAH
Realheart is developing Realheart® TAH, the first total artificial heart that mimics the structure and function of the native human heart. The recently approved patent covers a core technology of Realheart® TAH, namely an accurate and safe pressure measurements in medical environments. By enabling real-time monitoring, the patented sensor enables automated control of artificial hearts and circulatory support systems, such as Realheart® TAH, that is designed to provide a meaningful treatment alternative for patients awaiting a heart transplant, while providing benefits that may increase the quality of life. The structural design of Realheart® TAH aims to decrease risk factors commonly associated with currently approved artificial heart treatment devices, e.g., stroke, internal bleeding, and anaemia.
Country: China
Patent number: ZL2021800364839
Expiration date: March 18, 2041
Patent 2: patent in Japan covering realtime regulation of Realheart® TAH
The patent encompasses a control method and system setup for artificial heart devices that incorporates feedback mechanisms to manage cardiac output in real time. Through continuous tracking and automatic adjustment of essential factors like pressure, flow, and pump speed, the technology enables fully automated regulation of artificial hearts and circulatory support systems, including the Realheart® TAH. This ensures stable and optimized blood flow. The design is intended to integrate smoothly with both current and upcoming versions of the Realheart® TAH but can also be applied to other comparable devices.
Country: Japan
Patent number: JP7731894B2
Expiration date: March 18, 2041
Scandinavian Real Heart AB (publ) vill informera om en korrigering i den kallelse till extra bolagsstämma som publicerades den 24 oktober 2025.
I kallelsen angavs felaktigt att den extra bolagsstämman skulle hållas tisdagen den 24 november 2025. Det korrekta är: Måndagen den 24 november 2025
Observera att datumet 24 november 2025 är korrekt – endast veckodagen har justerats. Tid och plats för stämman är oförändrade.
Vi beklagar det inträffade felet och ber om ursäkt för eventuell förvirring. För mer information, vänligen se den uppdaterade kallelsen på vår webbplats eller kontakta bolaget.
Scandinavian Real Heart AB (publ) wishes to inform stakeholders of a correction in the notice published on 24 October 2025 regarding the Extraordinary General Meeting.
The notice incorrectly stated that the meeting would be held on Tuesday, 24 November 2025. The correct information is: Monday, 24 November 2025.
Please note that the date – 24 November 2025 – remains correct; only the weekday has been adjusted. The time and venue of the meeting are unchanged.
We regret the error and apologise for any confusion this may have caused. For further details, please refer to the updated notice on our website or contact the company directly.
Aktieägarna i Scandinavian Real Heart AB, org.nr. 556729-5588 (”Bolaget”), kallas härmed till extra bolagsstämma tisdagen den 24 november 2025 kl. 17.30 på Best Western Plus Hotel Plaza, Kopparbergsvägen 10, 722 13 Västerås. Inregistrering till stämman börjar kl. 17.00.
Rätt att delta vid stämman m.m.
Aktieägare som önskar delta vid stämman ska:
För att ha rätt att delta i stämman måste en aktieägare som låtit förvaltarregistrera sina aktier, förutom att anmäla sig till stämman, låta registrera aktierna i eget namn så att aktieägaren blir upptagen i framställningen av aktieboken per avstämningsdagen måndagen den 17 november 2025. Sådan omregistrering kan vara tillfällig (s.k. rösträttsregistrering) och begärs hos förvaltaren enligt förvaltarens rutiner i sådan tid i förväg som förvaltaren bestämmer. Rösträttsregistrering som gjorts av förvaltaren senast onsdagen den 19 november 2025 kommer att beaktas vid framställningen av bolagsstämmoaktieboken.
Ombud m.m.
Om aktieägare ska företrädas av ombud måste ombudet ha med skriftlig, daterad och av aktieägaren undertecknad fullmakt till stämman. Fullmakten får inte vara äldre än ett år om den inte anger att den är giltig under en längre tid, dock längst fem år. Om fullmakten utfärdats av juridisk person ska ombudet också ha med aktuellt registreringsbevis eller motsvarande behörighetshandling för den juridiska personen. För att underlätta inpasseringen bör kopia av fullmakt och andra behörighetshandlingar bifogas anmälan till stämman. Fullmaktsformulär hålls tillgängligt på Bolagets hemsida www.realheart.se och skickas med post till aktieägare som kontaktar Bolaget och uppger sin adress.
Behandling av personuppgifter
För information om hur personuppgifter behandlas i samband med bolagsstämman hänvisas till den integritetspolicy som finns tillgänglig på Euroclear Sweden AB:s hemsida: https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.
Förslag till dagordning
Punkt 1 – Val av ordförande vid stämman
Styrelsen föreslår att Jimmy Nybom väljs till ordförande på stämman.
Punkt 7 – Beslut om nyemission av aktier
Styrelsens förslag till beslut om nyemission av aktier, bilaga 1
Punkt 8 – Beslut om ändring av bolagsordningen
Styrelsens förslag till beslut om ändring av bolagsordningen, bilaga 2
Den föreslagna bolagsordningen i sin helhet, bilaga 3
Beslutet är villkorat av att stämman fattar beslut i enlighet med punkten 7 i kallelsen.
Majoritetskrav
För giltigt beslut enligt beslutspunkten 8 krävs att förslagen biträds av aktieägare med minst två tredjedelar av såväl de avgivna rösterna som de aktier som är företrädda vid stämman.
Uppgifter om antalet aktier och röster
Vid tidpunkten för utfärdandet av denna kallelse uppgår det totala antalet aktier och röster i Bolaget till 4 998 704 stycken.
Aktieägares rätt att erhålla upplysningar
Aktieägarna erinras om rätten att vid stämman begära upplysningar från styrelsen och verkställande direktören i enlighet med 7 kap. 32 § aktiebolagslagen (2005:551).
Tillhandahållande av handlingar
Handlingar enligt aktiebolagslagen kommer att hållas tillgängliga på Bolagets kontor senast två veckor före stämman och tillsändes utan kostnad den aktieägare som begär det och uppger sin postadress. Handlingarna kommer senast från denna tidpunkt även att finnas tillgängliga på Bolagets hemsida www.realheart.se. Samtliga ovanstående handlingar kommer även att framläggas på stämman.
Västerås i oktober 2025
Scandinavian Real Heart AB
STYRELSEN
The shareholders of Scandinavian Real Heart AB, org.nr. 556729-5588 (the "Company"), are hereby invited to attend the Extraordinary General Meeting to be held on Tuesday, November 24, 2025 at 5:30 p.m. at Best Western Plus Hotel Plaza, Kopparbergsvägen 10, 722 13 Västerås, Sweden. Registration for the meeting will commence at 5:00 p.m.
Right to participate in the meeting, etc.
Shareholders who wish to participate in the Meeting must:
In order to be entitled to participate in the meeting, a shareholder whose shares are registered in the name of a nominee must, in addition to giving notice of participation in the meeting, register the shares in their own name so that the shareholder is included in the presentation of the share register as of the record date of Monday, November 17, 2025. Such re-registration may be temporary (so-called voting rights registration) and is requested from the nominee in accordance with the nominee's procedures at such time in advance as determined by the nominee. Voting rights registration made by the nominee no later than Wednesday, November 19, 2025 will be taken into account in the preparation of the general meeting share register.
Agents, etc.
If a shareholder is to be represented by a proxy, the proxy must bring a written, dated and signed power of attorney to the meeting. The power of attorney may not be older than one year unless it specifies that it is valid for a longer period of time, but not more than five years. If the power of attorney has been issued by a legal entity, the representative must also bring the current certificate of registration or equivalent authorization document for the legal entity. To facilitate entry, a copy of the power of attorney and other authorization documents should be attached to the notification to the meeting. Proxy forms are available on the Company's website www.realheart.se and will be sent by mail to shareholders who contact the Company and state their address.
Processing of personal data
For information on how personal data is processed in connection with the Annual General Meeting, please refer to the privacy policy available on Euroclear Sweden AB's website: https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.
Draft agenda
Item 1 – Election of Chairman of the Meeting
The Board of Directors proposes that Jimmy Nybom be elected Chairman of the Meeting.
Item 7 – Resolution on new issue of shares
The Board of Directors' proposal for a resolution on a new issue of shares, appendix 1
Item 8 – Resolution to amend the Articles of Association
The Board of Directors' proposal for a resolution to amend the Articles of Association, appendix 2
The proposed Articles of Association in its entirety, appendix 3
The resolution is conditional upon the Annual General Meeting resolving in accordance with item 7 of the notice.
Majority requirements
A valid resolution under resolution item 8 requires that the proposals are supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the meeting.
Information on the number of shares and votes
At the time of issuing this notice, the total number of shares and votes in the Company amounts to 4,998,704.
Shareholders' right to receive information
Shareholders are reminded of the right to request information from the Board of Directors and the CEO at the Annual General Meeting in accordance with Chapter 7. Section 32 of the Swedish Companies Act (2005:551).
Provision of documents
Documents in accordance with the Swedish Companies Act will be available at the Company's office no later than two weeks prior to the Annual General Meeting and will be sent free of charge to the shareholder who so requests and states their postal address. The documents will also be available on the Company's website www.realheart.se at the latest from this date. All of the above documents will also be presented at the Annual General Meeting.
Västerås in October 2025
Scandinavian Real Heart
The Board of Directors
Västerås, Sweden, September 26, 2025 – Scandinavian Real Heart AB (publ) announces today that the company has been granted patent approval by the Japan Patent Office (JPO) concerning the automatic control of Realheart® TAH. While this is the first jurisdiction to approve the patent, the company has pending applications of the same patent in Europe, the US, India, China and Australia.
Realheart is developing Realheart® TAH, the first total artificial heart that mimics the structure and function of the native human heart. The recently approved patent (JP patent no. 7731894) covers a key technology of Realheart® TAH, entailing the automated control function of the device. The feature is an important part of the product’s value proposition, designed to provide a meaningful treatment alternative for patients awaiting a heart transplant, while providing benefits that may increase the quality of life. The structural design of Realheart® TAH aims to decrease risk factors commonly associated with currently approved artificial heart treatment devices, e.g., stroke, internal bleeding, and anemia.
The patent approval confers market protection for the device in Japan until 2041.
Västerås, Sweden, September 17, 2025 – Scandinavian Real Heart AB (publ) announces today that the company and its academic partner at Linköping University has published results from a scientific study evaluating a 3D-printed MRI-compatible artificial heart with advanced medical imaging that shows three-dimensional blood flow changes in real time (4D). The resultsshow that Realheart® TAH produces blood flow patterns comparable to those of the natural human heart, underscoring its potential as a safe and effective treatment for severe heart disease.
In the study, researchers used four dimensional (4D) flow MRI – an imaging approach that can capture three‑dimensional flow patterns in a human heart – combined with a physical, 3D‑printed model of Realheart® TAH to study its blood flow profile. This is the first time a 3D-printed pulsatile MRI-compatible artificial heart has been built and successfully evaluated with 4D flow MRI. Results from the study show that Realheart® TAH produces a blood flow profile comparable to the native human heart, further highlighting its potential as an effective treatment in cardiac disease.
“Our study demonstrates that the combination of 4D flow MRI with 3D printing is a powerful way to evaluate blood flow in artificial hearts. The levels of stagnant blood, energy loss, and turbulence that were found when evaluating Realheart® TAH were comparable to those observed in the native human heart. Further, by pairing 4D flow MRI with 3D printing, we add a valuable tool to complement computer simulations and blood testing in the design process of medical cardiac devices,” says Tino Ebbers, Professor in physiological measurements at Linköping University, Sweden.
In summary, the study results match earlier computer simulations, confirming low friction forces and little stagnant blood flow in Realheart® TAH. Overall, the blood flow showed a healthy profile – showing no greater risk of clots or other complications than in the human heart. Areas of slow flow, which can trigger clots, were similar to those in healthy human hearts, and turbulence levels – another clot and hemolysis risk – were even lower than in patients with valve disease.
“By combining cutting-edge imaging with precision engineering, we highlight, yet again, the great potential in our technology to address severe heart disease. The study results provide further validation of Realheart® TAH’s performance and its capability to generate an adequate blood health profile. Collectively, these data strengthen our position and provide further support toward clinical studies,” says Ina Laura Perkins, CEO, Realheart.
Link to the paper: https://rdcu.be/eGpzl
Summary of Interim Report April – June 2025
| Group Overview | 2025-04-01 | 2024-04-01 | 2025-01-01 | 2024-01-01 | 2024-01-01 |
| 2025-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2024-12-31 | |
| 3 mon | 3 mon | 6 mon | 6 mon | 12 mon | |
| Operating income | 20 592 | 30 322 | 90 586 | 40 380 | 50 054 |
| Earnings after financial items | -8 729 586 | -6 321 701 | -18 627 956 | -14 106 388 | -34 350 238 |
| Balance sheet total | 87 939 144 | 86 640 481 | 87 939 144 | 86 640 481 | 83 279 673 |
| Equity / assets ratio | 85% | 74% | 85% | 74% | 81% |
| Earnings per share | -1,98 | -0,07 | -4,23 | 0,15 | -16,61 |
| Number of shares* | 4 398 704 | 96 994 446 | 4 398 704 | 96 994 446 | 2 068 152 |
| Parent Company Overview | 2025-04-01 | 2024-04-01 | 2025-01-01 | 2024-01-01 | 2024-01-01 |
| 2025-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2024-12-31 | |
| 3 mon | 3 mon | 6 mon | 6 mon | 12 mon | |
| Operating income | 20 592 | 30 322 | 90 586 | 40 380 | 50 054 |
| Earnings after financial items | -8 618 743 | -6 158 452 | -18 458 587 | -13 922 442 | -32 409 725 |
| Balance sheet total | 90 551 912 | 87 141 085 | 90 551 912 | 87 141 085 | 85 837 128 |
| Equity / assets ratio | 86% | 74% | 86% | 74% | 82% |
| Earnings per share | -1,96 | -0,06 | -4,20 | -0,14 | -15,67 |
| Number of shares* | 4 398 704 | 96 994 446 | 4 398 704 | 96 994 446 | 2 068 152 |
* In November 2024, a reverse share split was carried out whereby 100 shares were combined into 1 share.
Revenue and Result
Scandinavian Real Heart AB is currently engaged in research and development and currently has no sales of its own products. Research and development costs incurred for Realheart® TAH were capitalized during the period April 1 – June 30, 2025, in the amount of SEK 6.7 million.
Employees
The number of employees in the Group at the end of the quarter was 12 full-time employees and 2 hourly employees.
Transactions With Related Parties
No significant transactions with related parties have taken place during the period.
Significant Risks and Uncertainties
Realheart’s focus is on getting through the preclinical phase (hemolysis, GLP studies in animals and endurance tests) to be able to start clinical studies. This means that the Company must finalize the version of both the controller and the heart pump to be included in these tests. Realheart must also hold parallel discussions with the Notified Body in the EU and with the FDA in the US to ensure the fastest and safest route for the product to market.
The Company is continuously working on measures to minimize delays. Furthermore, the continued product development requires that the Company can secure funding in both the short and long term. The board is continuously working on different scenarios to ensure the Company’s future operations.
Financial Position
At the end of the period, the Group’s cash and cash equivalents amounted to SEK 27.9 million. At present, the Group does not generate its own positive cash flow and is thus dependent on external financing. In order to solve the longer-term financing needs, the Board of Directors is continuously evaluating options for further capitalization of the Company.
CEO Comment
Over the last quarter, Realheart has been visible in several different forums. In a recently aired public service documentary in Germany and France, Realheart® TAH was showcased, putting the spotlight on artificial hearts as a future treatment option for heart failure patients. Shortly thereafter, our state-of-the-art system was described in a research article in the prestigious journal Artificial Organs. Together with strategic events, including the election of Oskar Mellgren as new chairman of the board, we remain topical while making essential strides forward in the development of Realheart® TAH.
Significant Events During the Second Quarter of the Year
During April, the company received a total of SEK 25.7 million before direct issue costs, which partly stems from payment for shares subscribed for in the directed issue that the board decided on in March 2025 and partly from payment for shares subscribed for through warrents of series TO3.
On April 29, Realheart announces that the company has been granted a patent approval by the Japan Patent Office (JPO) concerning a pressure sensor device for artificial hearts and circulatory support systems such as Realheart® TAH. The patent is a supportive measure to ensure market protection of the company’s device on the Japanese market and is valid until 2041.
On May 2, Realheart announces that EIC has Subscribed for 600,000 Shares in the Directed Share Issue Resolved by the Board of Directors of Realheart on 27 April 2025.
At the general meeting in June, two new board members were elected: Mia Tomczak and Oskar Mellgren, who was also elected chairman of the board.
On June 10, Realheart announces that the company’s technology is presented and showcased in a public service documentary broadcasted by ARTE TV, targeted at the German and French general public. The documentary features a visit to Realheart and showcases one of the company’s preclinical implantation procedures. Additionally, Realheart® TAH is demonstrated in the lab, highlighting its unique adaptive pressure system and the patient-friendly controller that is under development.
On June 17, Realheart announces that the company has been granted patent approval by the United States Patent and Trademark Office (USPTO) concerning the core technology of Realheart® TAH. The same patent has previously been approved in the European Patent Office (EPO). The patent approval confers market protection for the device in the US until 2037.
On June 18, Realheart announces that the company’s scientific collaborator at the Royal School of Technology (KTH) has published new results in the scientific journal Artificial Organs, validating the function of Realheart® TAH to produce systemic hemodynamic balance, as well as adaptively adjust the system’s cardiac output based on pressure sensor data. The new data are based on simulations from a state-of-the-art semi-virtual system financed through a joint strategic initiative between Vinnova, Formas and the Swedish Energy Agency (Energimyndigheten).
On June 27, Realheart announces that the company is shifting from issuing financial reports once per quarter to semi-annual reporting. The change is made as a strategic decision intended to free up time for the company’s management to be dedicated to the development of Realheart® TAH and increase cost efficiency. Consequently, the financial reporting will comprise three reports: one for the first half-year, one for the second half-year/full year, and an annual report.
Significant Events After the End of the Period
On July 7, Realheart announces that the company has received an outstanding payment of approximately SEK 6.8 million from the European Innovation Council (EIC) following the company’s directed share issue communicated on May 2, 2025, wherein it was announced that EIC has subscribed 600,000 shares to the subscription price of SEK 11.31 per share.
On August 11, Realheart announces that the company has received its third disbursement from the European Innovation Council (EIC) grant, initially awarded in December 2021. The grant aims to support the development of the artificial heart Realheart® TAH. The payment of EUR 250,000 equals 10% of the total grant sum of EUR 2.5 million.
Västerås, Sweden, August 11, 2025 – Scandinavian Real Heart AB (publ) announces today that the company has received its third disbursement from the European Innovation Council (EIC) grant, initially awarded in December 2021. The grant aims to support the development of the artificial heart Realheart® TAH. The payment of EUR 250,000 equals 10% of the total grant sum of EUR 2.5 million.
The company was awarded a EUR 2.5 million grant within the framework of the European Innovation Council Accelerator program, aimed at supporting European innovations that have the potential to create new markets or disrupt existing ones. The grant continues to serve as a valuable mark of excellence that has enhanced the company's international standing among distinguished clinics and industry experts.
“We’re glad to receive the third disbursement from the European Innovation Council as part of its support for the development of Realheart® TAH. The funds will be used as part of our current efforts to further improve our quality workflows and accelerate production capabilities,” says Ina Laura Perkins, CEO, Realheart.
Västerås, Sweden, July 7, 2025 – Scandinavian Real Heart AB (publ) announces today that the company has received an outstanding payment of approximately SEK 6.8 million from the European Innovation Council (EIC) following the company’s directed share issue communicated on May 2, 2025, wherein it was announced that EIC has subscribed 600,000 shares to the subscription price of SEK 11.31 per share.
The European Innovation Council (EIC) has hitherto subscribed in two separate share issues resolved by the company. Due to the size of the investment and that Realheart acts within a sector of interest to the Swedish state, the transaction has been reviewed according to the Foreign Direct Investment Act, causing a delay in the payment.
“This settlement marks the completion of EIC’s participation in yet another financing round for the continued development of our unique technology. In this highly competitive arena, where only one in twenty applying companies receive any form of EIC support, we see this investment as an important external validation of the company’s innovation and potential. We look forward to continuing our constructive dialogue with the agency,” says Ina Laura Perkins, CEO, Realheart.
Västerås, Sweden, June 27, 2025 – Scandinavian Real Heart AB (publ) announces today that the company is shifting from issuing financial reports once per quarter to semi-annual reporting. The change is made as a strategic decision intended to free up time for the company’s management to be dedicated to the development of Realheart® TAH and increase cost efficiency. Consequently, the financial reporting will comprise three reports: one for the first half-year, one for the second half-year/full year, and an annual report.
The decision to shift from quarterly to biannual reporting follows the company’s internal overview and is an initiative to increase product development efficiency and decrease company costs. The transition is made in accordance with marketplace rules (First North Growth Market Rulebook, chapter 4.4). The company will continue to update the market via its official channels, including press releases and social media, on notable events connected to the company’s activities. As previously communicated, all future communications from Realheart will be in English.
Västerås, Sverige, 18 juni 2025 – Scandinavian Real Heart AB (publ) meddelar idag att bolagets vetenskapliga samarbetspartner vid Kungliga Tekniska Högskolan (KTH) har publicerat nya resultat i den vetenskapliga tidskriften Artificial Organs, som validerar Realheart® TAH:s funktion att skapa systemisk hemodynamisk balans, samt adaptivt justera systemets hjärtminutvolym baserat på data från trycksensorer. De nya resultaten är baserade på simuleringar från den senaste tekniken av ett semi-virtuellt system som finansierats genom ett gemensamt strategiskt initiativ mellan Vinnova, Formas och Energimyndigheten.
De publicerade resultaten visar att Realheart® TAHs automatiska kontrollalgoritm upprätthåller en korrekt vänster-högerbalans, vilket balanserar blodtrycket mellan systemisk cirkulation och lungcirkulation i hjärt-kärlsystemet. Vidare visar data att Realheart® TAH automatiskt ökade hjärtminutvolymen med upp till 2,1 gånger under träning från vila och minskade hjärtminutvolymen med 25 % under sömn samtidigt som trycket i förmaken hölls stabilt. Detta visades i simuleringar som utvärderade ett friskt tillstånd, samt i varierande nivåer av pulmonell hypertension. Sammantaget visar dessa resultat på enhetens förmåga att anpassa sig till snabba övergångar mellan fysiologiska tillstånd.
"Våra data visar att Realheart® TAH utmärker sig genom sin förmåga att möjliggöra olika nivåer av fysisk aktivitet för patienter som vill fortsätta att vara aktiva. Kombinationen av trycksensorbaserad återkopplingskontroll och pumpmekanismens förmåga att tillhandahålla ett träningsflöde gör den unik. Vi ser fram emot att genomföra ytterligare studier och utvärdera den mot de produkter som för närvarande är godkända", säger Dr. Seraina Dual, biträdande professor i biomedicinsk signalbehandling vid institutionen för biomedicinsk teknik och hälsosystem, Kungliga Tekniska Högskolan, Sverige.
Studien bygger på ett gemensamt projekt mellan Realheart och KTH, som har byggt en toppmodern kardiovaskulär ”hybridsimulator”, som inkluderar en digital modell av hjärta, lungor och kärl som kan kopplas fysiskt till Realheart® TAH. Uppsättningen möjliggör simuleringar av patientspecifika scenarier och förfining av pumpens styralgoritmer. Projektet möjliggörs av två bidrag på totalt 8 miljoner kronor, finansierade av Vinnovas program Smart Elektronik, ett samarbete med Formas och Energimyndigheten.
"Objektiva studier av vår enhets fysiologiska kontroll, utförda av experter inom forskningsområdet, är av avgörande betydelse för att öka vår innovations övergripande trovärdighet och förtroende, visa dess prestanda och potential samt lära oss om områden där vi kan fortsätta att förbättra oss. Genom att använda hybridsystemet kan vi genomföra snabba iterativa utvecklingscykler för att justera mjukvaran och snabbt testa ett stort antal olika fysiologiska scenarier", säger Ina Laura Perkins, VD, Realheart.
Artikeln ”Physiological Control of Realheart® Total Artificial Heart” är publicerad i Artificial Organs vol. 17 juni, 2025.
https://onlinelibrary.wiley.com/doi/10.1111/aor.15036